Stock Institutional Ownership and Shareholders

SecurityPTX / Pernix Therapeutics Holdings, Inc. (71426V108)
CHAIRMAN OF THE BOARD AND CEOSedor John A
Institutional Owners34
Institutional Shares2,239,052
Outstanding Shares16,520,000 (as of 2017-09-30)
Institutional Value$ 6,392,000 USD
Related 71426VAK4 / Pernix Therapeutics Holdings, Inc. Convertible Debt 4.25%
71426VAJ7 / Pernix Therapeutics Holdings, Inc. Debt 4.25%

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has 34 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,239,052 shares. Largest shareholders include Renaissance Technologies LLC, Vanguard Group Inc, Highbridge Capital Management Llc, Aisling Capital LLC, BlackRock Inc., California Public Employees Retirement System, Kcg Holdings, Inc., Group One Trading, L.p., Jacobs Levy Equity Management, Inc, and Cetera Investment Advisers.



Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ownership summary shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev Shares Current Shares Change
(Percent)
Prev Value (x$1000) Current Value (x$1000) Change
(Percent)
2017-08-14 13F-HR WOLVERINE TRADING, LLC Put 11,400 0 -100.00 42 0 -100.00
2017-11-14 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 39,300 61,721 57.05 158 194 22.78
2017-11-14 13F-HR Tower Research Capital LLC (TRC) 1,236 0 -100.00 5 0 -100.00
2017-11-13 13F-HR Evercore Wealth Management, LLC 5 5 0.00 0 0
2017-11-14 13F-HR BANK OF AMERICA CORP /DE/ 8,284 0 -100.00 33 0 -100.00
2017-11-14 13F-HR BlackRock Inc. 205,280 206,808 0.74 825 651 -21.09
2017-10-25 13F-HR SIMPLEX TRADING, LLC Put 10 3 -70.00 1 1 0.00
2017-11-13 13F-HR NORTHERN TRUST CORP 14,141 14,141 0.00 57 44 -22.81
2017-11-09 13F-HR JP MORGAN CHASE & CO 100 100 0.00 0 0
2017-11-15 13F-HR GROUP ONE TRADING, L.P. 0 13,120 0 41
2017-10-30 13F-HR IFP Advisors, Inc 302 302 0.00 1 1 0.00
2017-07-18 13F-HR/A-4 BOOTHBAY FUND MANAGEMENT, LLC 18,063 0 -100.00 193 0 -100.00
2017-11-14 13F-HR GOLDMAN SACHS GROUP INC 0 15,661 0 49
2017-11-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 247,100 42,200 -82.92 993 133 -86.61
2017-08-10 13F-HR FNY Partners Fund LP 500 0 -100.00 1 0 -100.00
2017-11-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 20,175 13,096 -35.09 13 41 215.38
2017-11-14 13F-HR UBS Group AG 1,141 2,637 131.11 5 8 60.00
2017-11-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 0 33,100 0 104
2017-11-14 13F-HR D. E. Shaw & Co., Inc. 12,609 0 -100.00 51 0 -100.00
2017-11-14 13F-HR Covington Capital Management 1,000 3
2017-08-14 13F-HR WOLVERINE TRADING, LLC 10,585 0 -100.00 39 0 -100.00
2017-11-06 13F-HR Advisor Group, Inc. 977 177 -81.88 4 1 -75.00
2017-07-31 SC 13G HIGHBRIDGE CAPITAL MANAGEMENT LLC 229,419
2017-11-14 13F-HR ROYAL BANK OF CANADA 103 103 0.00 0 0
2017-10-27 13F-HR Searle & Co. 17,250 17,250 0.00 69 54 -21.74
2017-11-14 13F-HR MORGAN STANLEY 26,618 21,694 -18.50 107 69 -35.51
2017-11-14 13F-HR Shanda Payment Holdings Ltd. 0 1,000 0 3
2017-11-06 13F-HR Bank of New York Mellon Corp 24,553 24,584 0.13 99 77 -22.22
2017-11-14 13F-HR VANGUARD GROUP INC 402,423 327,390 -18.65 1,617 1,031 -36.24
2017-11-16 13F-HR Cetera Investment Advisers 46,750 46,750 0.00 188 147 -21.81
2017-11-08 13F-HR Nelson, Van Denburg & Campbell Wealth Management Group, LLC 70 70 0.00 0 0
2017-11-08 13F-HR Dynamic Technology Lab Private Ltd 0 11,937 0 37
2017-11-13 13F-HR Renaissance Technologies LLC 800,050 818,950 2.36 3,216 2,580 -19.78
2017-10-25 13F-HR SIMPLEX TRADING, LLC Call 209 22 -89.47 7 2 -71.43
2017-11-14 13F-HR DEUTSCHE BANK AG\ 301 1 -99.67 1 0 -100.00
2017-11-14 13F-HR VALLEY NATIONAL ADVISERS INC 6 0
2017-11-09 13F-HR WELLS FARGO & COMPANY/MN 176 176 0.00 1 1 0.00
2017-10-17 13F-HR Cutler Group LP Call 3,000 0 -100.00 1 0 -100.00
2017-08-14 13F-HR WOLVERINE TRADING, LLC Call 19,700 0 -100.00 73 0 -100.00
2017-11-15 13F-HR GROUP ONE TRADING, L.P. Put 7,600 100 -98.68 31 0 -100.00
2017-11-14 13F-HR Jefferies Group LLC Put 342,400 0 -100.00 1,376 0 -100.00
2017-11-09 13F-HR CITADEL ADVISORS LLC Call 19,200 14,100 -26.56 77 44 -42.86
2017-11-09 13F-HR Aisling Capital LLC 210,000 210,000 0.00 844 662 -21.56
2017-11-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 37,480 82,838 121.02 151 261 72.85
2017-11-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 39,813 39,813 0.00 160 125 -21.87
2017-11-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 9 14 55.56 0 0
2017-08-11 13F-HR KCG HOLDINGS, INC. 28,739 76,964 167.80 106 309 191.51
2017-11-15 13F-HR GROUP ONE TRADING, L.P. Call 58,100 64,300 10.67 234 203 -13.25
2017-11-14 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 85 0 -100.00 0 0
2017-10-25 13F-HR SIMPLEX TRADING, LLC 6,507 1,267 -80.53 26 3 -88.46
2017-11-14 13F-HR BARCLAYS PLC 58 58 0.00 0 0

Stock Research Report

Pernix Therapeutics is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its strategy is to continue to create shareholder value by:

  • growing sales of the existing products in its portfolio in various ways, including identifying new growth opportunities; and
  • acquiring additional marketed specialty products or products close to regulatory approval to leverage its existing expertise and infrastructure.

Pernix Therapeutics target underserved segments, such as central nervous system (CNS) indications, including neurology, pain and psychiatry. The company promote its core branded products to physicians through its sales forces. The company market its generic products through its wholly owned subsidiaries, Macoven and Cypress.

Its branded products include Treximet, a medication indicated for the acute treatment of migraine attacks, with or without aura, ...

Click for full article
CUSIP: 71426V108